0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up

Brian J. McMahon, MD; Dana L. Bruden, MS; Kenneth M. Petersen, MD; Lisa R. Bulkow, MS; Alan J. Parkinson, PhD; Omana Nainan, PhD; Marina Khristova, PhD, DSc; Carolyn Zanis, BS; Helen Peters, BS; and Harold S. Margolis, MD
[+] Article and Author Information

From Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, and the Alaska Native Medical Center, Anchorage, Alaska; and the Centers for Disease Control and Prevention, Atlanta, Georgia.


Acknowledgments: The authors acknowledge the support they received from the many Community Health Aides in the study villages and the nurses at the Arctic Investigations Program and the Alaska Native Medical Center who over the years gave their valuable time to the study.

Grant Support: Partial support through the Alaska Native Tribal Health Consortium from the Division of Viral Hepatitis, National Centers for Infectious Diseases, Centers for Disease Control and Prevention Cooperative Agreement CA #U50/CCU022279. Merck & Co., Inc., West Point, Pennsylvania, supplied the vaccine and partially funded transportation during the first 10 years of follow-up through an unrestricted grant.

Potential Financial Conflicts of Interest: Grants received : B.J. McMahon (Merck Pharmaceuticals); Stock ownership or options (other than mutual funds): A.J. Parkinson (Merck & Co., Inc.).

Requests for Single Reprints: Brian J. McMahon, MD, Arctic Investigations Program, Centers for Disease Control and Prevention, 4055 Tudor Center Drive, Anchorage, AK 99508; e-mail, bdm9@cdc.gov.

Current Author Addresses: Dr. McMahon, Ms. Bruden, Ms. Bulkow, Dr. Parkinson, Ms. Zanis, and Ms. Peters: Arctic Investigations Program, Centers for Disease Control and Prevention, 4055 Tudor Center Drive, Anchorage, AK 99508.

Dr. Peterson: 13101 Floral Lane, Anchorage, AK 99516.

Drs. Nainan, Khristova, and Margolis: Viral Hepatitis Division, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333.

Author Contributions: Conception and design: B.J. McMahon, L.R. Bulkow, A.J. Parkinson.

Analysis and interpretation of the data: B.J. McMahon, D.L. Bruden, K.M. Petersen, L.R. Bulkow, M. Khristova.

Drafting of the article: B.J. McMahon, A.J. Parkinson, O. Nainan, M. Khristova.

Critical revision of the article for important intellectual content: B.J. McMahon, D.L. Bruden, K.M. Petersen, L.R. Bulkow, O. Nainan, H.S. Margolis.

Final approval of the article: B.J. McMahon, A.J. Parkinson, C. Zanis, H.V. Peters, H.S. Margolis.

Provision of study materials: K.M. Petersen, C. Zanis, H.V. Peters.

Statistical expertise: D.L. Bruden, L.R. Bulkow.

Obtaining of funding: H.S. Margolis.

Administrative, technical, or logistic support: O. Nainan, H.S. Margolis.

Collection and assembly of data: O. Nainan, M. Khristova, C. Zanis, H.V. Peters, H.S. Margolis.


Ann Intern Med. 2005;142(5):333-341. doi:10.7326/0003-4819-142-5-200503010-00008
Text Size: A A A

Since the last report on this cohort (14), 967 (61%) persons were tested at 11 years (November 1992) and 841 (53%) persons were tested at 15 years (November 1996) after their first dose of vaccine (Appendix Table 1). Sixteen persons had evidence of definite HBV infection, of whom 10 were tested at the 15-year follow-up. Seventy-eight persons had received an additional dose of vaccine, of whom 48 were drawn at the 15-year follow-up. Levels of anti-HBs were used in analysis from 783 (93%) of the 841 persons tested at 15 years (Appendix Table 1).

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Does Hepatitis B Vaccination Protection Continue after 15 Years?

The summary below is from the full report titled “Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up.” It is in the 1 March 2005 issue of Annals of Internal Medicine (volume 142, pages 333-341). The authors are B.J. McMahon, D.L. Bruden, K.M. Petersen, L.R. Bulkow, A.J. Parkinson, O. Nainan, M. Khristova, C. Zanis, H. Peters, and H.S. Margolis.

Read More...

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)